(Q38051706)

27 August 2017

title

Drug choices in autoimmune hepatitis: part B--Nonsteroids (English)

1 reference

27 August 2017

1 reference

Albert J Czaja

1

1 reference

27 August 2017

publication date

1 September 2012

1 reference

Expert Review of Gastroenterology & Hepatology

27 August 2017

published in

1 reference

27 August 2017

volume

6

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

617-635

1 reference

Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared

27 August 2017

cites work

1 reference

Current and future treatments of autoimmune hepatitis

21 January 2018

1 reference

Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis

21 January 2018

1 reference

Advances in the current treatment of autoimmune hepatitis

21 January 2018

1 reference

Autoimmune hepatitis. Part A: pathogenesis

21 January 2018

1 reference

Cost-effectiveness of pharmacotherapy for autoimmune hepatitis

21 January 2018

1 reference

Diagnosis and management of autoimmune hepatitis

21 January 2018

1 reference

Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal

21 January 2018

1 reference

Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease

21 January 2018

1 reference

Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.

21 January 2018

1 reference

Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus

21 January 2018

1 reference

Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.

21 January 2018

1 reference

A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis

21 January 2018

1 reference

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

21 January 2018

1 reference

Mycophenolate mofetil for autoimmune hepatitis: a single practice experience

21 January 2018

1 reference

Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.

21 January 2018

1 reference

Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

21 January 2018

1 reference

Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations.

21 January 2018

1 reference

Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites.

21 January 2018

1 reference

Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients

21 January 2018

1 reference

The clinical pharmacology of 6-mercaptopurine

21 January 2018

1 reference

Immunosuppressive drugs: the first 50 years and a glance forward

21 January 2018

1 reference

Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety

21 January 2018

1 reference

Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications

21 January 2018

1 reference

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines

21 January 2018

1 reference

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications

21 January 2018

1 reference

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease

21 January 2018

1 reference

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

21 January 2018

1 reference

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms

21 January 2018

1 reference

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

21 January 2018

1 reference

Clinical pharmacology and pharmacogenetics of thiopurines

21 January 2018

1 reference

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

Antifibrotic actions of mycophenolic acid

21 January 2018

1 reference

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration

21 January 2018

1 reference

Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis

21 January 2018

1 reference

Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease

21 January 2018

1 reference

Clinical pharmacokinetics of mycophenolate mofetil

21 January 2018

1 reference

Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation

21 January 2018

1 reference

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients

21 January 2018

1 reference

Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation

21 January 2018

1 reference

Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients

21 January 2018

1 reference

Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft

21 January 2018

1 reference

Use of mycophenolate mofetil in liver transplantation: a literature review.

21 January 2018

1 reference

Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature.

21 January 2018

1 reference

Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation

21 January 2018

1 reference

Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients

21 January 2018

1 reference

Pharmacokinetics of mycophenolate mofetil and sirolimus in children.

21 January 2018

1 reference

Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus.

21 January 2018

1 reference

Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers

21 January 2018

1 reference

Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report.

21 January 2018

1 reference

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis

21 January 2018

1 reference

Therapy of autoimmune hepatitis

21 January 2018

1 reference

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience

21 January 2018

1 reference

Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury

21 January 2018

1 reference

Severe villus atrophy and chronic malabsorption induced by azathioprine

21 January 2018

1 reference

Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy

21 January 2018

1 reference

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine

21 January 2018

1 reference

Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience

21 January 2018

1 reference

Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree.

21 January 2018

1 reference

Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients

21 January 2018

1 reference

Mycophenolate mofetil--is it worth the cost? The in-favor opinion

21 January 2018

1 reference

Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis.

21 January 2018

1 reference

Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis

21 January 2018

1 reference

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

21 January 2018

1 reference

Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis

21 January 2018

1 reference

Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis

21 January 2018

1 reference

Long-term prognosis in patients with severe late radiation enteropathy: a prospective cohort study

21 January 2018

1 reference

Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient.

21 January 2018

1 reference

Inhibitors of the calcineurin/NFAT pathway.

21 January 2018

1 reference

NFAT and NF-kappaB factors-the distant relatives

21 January 2018

1 reference

NFAT proteins: key regulators of T-cell development and function

21 January 2018

1 reference

Calcineurin activation by slow calcium release from intracellular stores suppresses protein kinase C regulation of L-type calcium channels in L6 cells

21 January 2018

1 reference

Distribution of cyclosporin in organ transplant recipients

21 January 2018

1 reference

Molecular aspects of cyclophilins mediating therapeutic actions of their ligands

21 January 2018

1 reference

Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial growth factor

21 January 2018

1 reference

Molecular and biological actions of cyclosporin A and FK506 on T cell development and function

21 January 2018

1 reference

Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics

21 January 2018

1 reference

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

21 January 2018

1 reference

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin

21 January 2018

1 reference

Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12

21 January 2018

1 reference

Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus

21 January 2018

1 reference

Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.

21 January 2018

1 reference

Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring

21 January 2018

1 reference

A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue

21 January 2018

1 reference

Pharmacology and pharmacokinetics of cyclosporine

21 January 2018

1 reference

An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients

21 January 2018

1 reference

Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).

21 January 2018

1 reference

Clinical pharmacokinetics of tacrolimus

21 January 2018

1 reference

Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring

21 January 2018

1 reference

Clinical implications of CYP3A polymorphisms

21 January 2018

1 reference

Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors

21 January 2018

1 reference

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

21 January 2018

1 reference

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

21 January 2018

1 reference

Cyclosporine pharmacokinetic drug interactions

21 January 2018

1 reference

Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome

21 January 2018

1 reference

A risk-benefit assessment of tacrolimus in transplantation

21 January 2018

1 reference

Tacrolimus: a further update of its use in the management of organ transplantation

21 January 2018

1 reference

Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders

21 January 2018

1 reference

Biochemical mechanisms of cyclosporine neurotoxicity

21 January 2018

1 reference

Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.

21 January 2018

1 reference

Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.

21 January 2018

1 reference

Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation

21 January 2018

1 reference

Autoimmune hepatitis after liver transplantation

21 January 2018

1 reference

Upstream and downstream of mTOR

21 January 2018

1 reference

TOR signaling in growth and metabolism

21 January 2018

1 reference

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

21 January 2018

1 reference

Rapamycin successfully treats post-transplant autoimmune hepatitis

21 January 2018

1 reference

Retracted: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells

21 January 2018

1 reference

Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients

21 January 2018

1 reference

Rapamycin-induced cytotoxic signal transduction pathway

21 January 2018

1 reference

Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells

21 January 2018

1 reference

Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells

21 January 2018

1 reference

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

21 January 2018

1 reference

A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration

21 January 2018

1 reference

Metabolic interaction between cyclosporine and sirolimus

21 January 2018

1 reference

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

21 January 2018

1 reference

Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies

21 January 2018

1 reference

Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients

21 January 2018

1 reference

Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing

21 January 2018

1 reference

Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus

21 January 2018

1 reference

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

Sirolimus-induced pneumonitis following liver transplantation.

21 January 2018

1 reference

C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective

21 January 2018

1 reference

New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation

21 January 2018

1 reference

From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy

21 January 2018

1 reference

Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives

21 January 2018

1 reference

Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis

21 January 2018

1 reference

Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EGH.12.38

1 reference

27 August 2017

1 reference